THERAPEUTIC VACCINES TO REDUCE OCULAR HSV RECURRENCE

描述(改编自申请人的摘要)： 这项建议建议减少由疱疹引起的发病率。 通过治疗性疫苗接种致盲。在之前的研究中 在此期间，研究人员已表明治疗性疫苗在 具有统计学意义的术语减少HSV-1眼部复发 疾病和HSV-1脱落。调查员推测， 疫苗的治疗效果是由于局部的眼/粘膜免疫 而不是全身免疫反应。调查员的 小组撰写了四篇与他们的工作直接相关的论文 治疗性疫苗接种。所有的论文都已在此时提交 (无人接受)。目前要解决的具体目标 应用是(1)检验治疗性疫苗的假设 眼部HSV-1复发的疗效和持续时间可通过以下方式延长 用亚单位疫苗或HSV-1加强眼周接种 DNA眼球疫苗或HSV-1眼球活疫苗；(2)检测 假设治疗性疫苗对眼部复发有效 HSV-1是由于常见的粘膜免疫，而不仅仅是局部眼部免疫 黏膜免疫；以及(3)验证SIgA是 治疗性疫苗最重要的特异性黏膜免疫反应 治疗眼部HSV-1复发的疗效观察

DESCRIPTION (Adapted from the applicant's abstract): This proposal proposes to reduce the incidence of herpes induced blindness through therapeutic vaccination. In the previous research period, the investigator has indicated therapeutic vaccine efficacy in terms of statistically significant that reduced recurrent HSV-1 ocular disease and HSV-1 shedding. The investigator has hypothesized that the therapeutic vaccine efficacy seen is due to local ocular/mucosal immune response rather than a systemic immune response. The investigator's group has produced four papers directly related to their work on therapeutic vaccination. All papers have been submitted at this time (none accepted). The specific aims to be addressed in the present application are (1) to test the hypothesis that therapeutic vaccine efficacy and duration against recurrent ocular HSV-1 can be extended by periocular booster inoculations with a subunit vaccine, or with HSV-1 DNA ocular vaccines or live HSV-1 ocular vaccines; (2) to test the hypothesis that therapeutic vaccine efficacy against recurrent ocular HSV-1 is due to common mucosal immunity rather than just local ocular mucosal immunity; and (3) to verify the hypothesis that sIgA is the specific mucosal immune response most important for therapeutic vaccine efficacy against recurrent ocular HSV-1.